Jayaraj John Marshal, Jothimani Muralidharan, Palanisamy Chella Perumal, Pentikäinen Olli T, Pannipara Mehboobali, Al-Sehemi Abdullah G, Muthusamy Karthikeyan, Gopinath Krishnasamy
Pharmacogenomics and CADD Lab, Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India.
State Key Laboratory of Biobased Materials and Green Paper Making, School of Food Science and Engineering, Qilu University of Technology, Shandong Academy of Sciences, Jinan, Shandong, China.
Bioinorg Chem Appl. 2022 Mar 25;2022:8635054. doi: 10.1155/2022/8635054. eCollection 2022.
COVID-19 is more virulent and challenging to human life. In India, the Ministry of AYUSH recommended some strategies through Siddha, homeopathy, and other methods to effectively manage COVID-19 (Guidelines for AYUSH Clinical Studies in COVID-19, 2020). and homeopathy medicines are in use for the prevention and treatment of COVID-19 infection; however, the mechanism of action is less explored. This study aims to understand the antagonist activity of natural compounds found in Kabasura Kudineer and homeopathy medicines against the SARS-CoV-2 using computational methods. Potential compounds were screened against NSP-12, NSP-13, NSP-14, NSP-15, main protease, and spike proteins. Structure-based virtual screening results shows that, out of 14,682 Kabasura Kudineer compounds, the 250395, 129677029, 44259583, 44259584, and 88583189 compounds and, out of 3,112 homeopathy compounds, the 3802778, 320361, 5315832, 14590080, and 74029795 compounds have good scoring function against the SARS-CoV-2 structural and nonstructural proteins. As a result of docking, homeopathy compounds have a docking score ranging from -5.636 to 13.631 kcal/mol, while Kabasura Kudineer compounds have a docking score varying from -8.290 to -13.759 kcal/mol. It has been found that the selected compounds bind well to the active site of SARS-CoV-2 proteins and form hydrogen bonds. The molecular dynamics simulation study shows that the selected compounds have maintained stable conformation in the simulation period and interact with the target. This study supports the antagonist activity of natural compounds from Kabasura Kudineer and homeopathy against SARS-CoV-2's structural and nonstructural proteins.
新型冠状病毒肺炎(COVID-19)对人类生命更具致病性且更具挑战性。在印度,印度草医学、顺势疗法及其他医学部通过悉达医学、顺势疗法和其他方法推荐了一些有效管理COVID-19的策略(《COVID-19中印度草医学临床研究指南》,2020年)。顺势疗法药物正用于预防和治疗COVID-19感染;然而,其作用机制尚少被探究。本研究旨在使用计算方法了解卡巴萨拉苦地那尔(Kabasura Kudineer)和顺势疗法药物中发现的天然化合物对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的拮抗活性。针对非结构蛋白12(NSP-12)、非结构蛋白13(NSP-13)、非结构蛋白14(NSP-14)、非结构蛋白15(NSP-15)、主要蛋白酶和刺突蛋白筛选潜在化合物。基于结构的虚拟筛选结果显示,在14682种卡巴萨拉苦地那尔化合物中,编号为250395、129677029、44259583、44259584和88583189的化合物,以及在3112种顺势疗法化合物中,编号为3802778、320361、5315832、14590080和74029795的化合物对SARS-CoV-2结构蛋白和非结构蛋白具有良好的评分功能。对接结果显示,顺势疗法化合物的对接分数范围为-5.636至13.631千卡/摩尔,而卡巴萨拉苦地那尔化合物的对接分数在-8.290至-13.759千卡/摩尔之间变化。已发现所选化合物与SARS-CoV-2蛋白的活性位点结合良好并形成氢键。分子动力学模拟研究表明,所选化合物在模拟期间保持稳定构象并与靶点相互作用。本研究支持卡巴萨拉苦地那尔和顺势疗法中的天然化合物对SARS-CoV-2结构蛋白和非结构蛋白的拮抗活性。